Search results
Results from the Tech24 Deals Content Network
Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Dexamyl is the recreational drug of choice for the main character of the film Quadrophenia, who eventually suffers from amphetamine psychosis. They were widely abused. [ 4] In the late 1960s and early 1970s, Dexamyl spansules—a clear and green capsule containing green and white "beads"—became popular as a street-drug upper nicknamed ...
e. Orlistat (Xenical), the most commonly used medication to treat obesity and sibutramine (Meridia), a medication that was withdrawn due to cardiovascular side effects. Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of ...
Pfizer announced on Dec. 1 that it was discontinuing phase 3 clinical trials of the twice-daily version due to high rates of adverse side effects. While these were mostly mild, a large percentage ...
The Biden administration on Thursday announced Medicare negotiated discounts with pharmaceutical companies on 10 drugs prescribed to treat blood clots, cancer, heart disease, and diabetes. The ...
Weight loss in those receiving the fen-phen combination was significantly greater (8.4±1.1 kg) than in those receiving placebo (4.4±0.9 kg) and equivalent to that of those receiving fenfluramine (7.5±1.2 kg) or phentermine alone (10.0±1.2 kg). This amounts to an additional weight loss of 4±2 kg over the course of 24 weeks.
During menopause, your body and brain undergo some radical shifts that can contribute to the development of an eating disorder. New hormone fluctuations not only impact your sleep and mood, but ...
Sibutramine is a serotonin–norepinephrine reuptake inhibitor (SNRI) that, in humans, reduces the reuptake of norepinephrine (by ~73%), serotonin (by ~54%), and dopamine (by ~16%), [ 22] thereby increasing the levels of these substances in synaptic clefts and helping enhance satiety; the serotonergic action, in particular, is thought to ...